TrovaGene Inc (NASDAQ:TROV) shares fell 5.2% during mid-day trading on Friday . The stock traded as low as $1.05 and last traded at $1.10. 3,347,725 shares traded hands during mid-day trading, an increase of 347% from the average session volume of 749,253 shares. The stock had previously closed at $1.16.

Several research firms have recently issued reports on TROV. Maxim Group restated a “buy” rating on shares of TrovaGene in a research report on Monday, August 6th. Zacks Investment Research raised TrovaGene from a “sell” rating to a “hold” rating in a research note on Tuesday, September 11th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. TrovaGene presently has an average rating of “Hold” and a consensus target price of $4.75.

The company has a market capitalization of $18.57 million, a P/E ratio of -0.18 and a beta of -0.10.

TrovaGene (NASDAQ:TROV) last issued its quarterly earnings data on Friday, August 3rd. The medical research company reported ($0.44) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.33) by ($0.11). The business had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.10 million. TrovaGene had a negative return on equity of 188.93% and a negative net margin of 2,970.66%.

An institutional investor recently raised its position in TrovaGene stock. Renaissance Technologies LLC increased its holdings in shares of TrovaGene Inc (NASDAQ:TROV) by 58.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 203,802 shares of the medical research company’s stock after buying an additional 75,131 shares during the quarter. Renaissance Technologies LLC owned 1.15% of TrovaGene worth $157,000 as of its most recent SEC filing. 8.89% of the stock is currently owned by institutional investors and hedge funds.

TrovaGene Company Profile (NASDAQ:TROV)

Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor.

See Also: Momentum Indicator: Relative Strength Index

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.